{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":832,"total_is_capped":false,"direct_labels_cover":9,"predictions_cover":832,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"ca2496bf98f8","filters":{"venue":"The Lancet Oncology"}},"results":[{"id":"W2158681922","doi":"10.1016/s1470-2045(09)70025-7","title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7801,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Ontario Institute for Cancer Research; Queen's University; Hôpital Notre-Dame; Western University; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Temozolomide; Radiation therapy; Concomitant; Internal medicine; Hazard ratio; Clinical endpoint; Oncology; Adjuvant; Cancer; Clinical trial; Surgery; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.02105482544595683,"gpt":0.3383414721996334,"spread":0.3172866467536766,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001034888,0.0002012873,0.002074958,0.0002989651,0.0000311802,0.00000472601,0.0001558564,0.00008981375,0.00001605379],"category_scores_gemma":[0.0001128066,0.00009877042,0.0001552432,0.0008582099,0.0001761096,0.00001822079,0.00001250356,0.0002005326,1.775894e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00023632,"about_ca_system_score_gemma":0.0001166313,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002290475,"about_ca_topic_score_gemma":0.002129935,"domain_scores_codex":[0.9978578,0.0008801051,0.0004836944,0.0002647096,0.0002549969,0.0002587126],"domain_scores_gemma":[0.9972085,0.001966028,0.00030574,0.0004350233,0.00003332354,0.00005143518],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9358662,0.007526355,0.03387414,0.00001722862,0.002765465,0.0002565104,0.002578752,0.0002582259,0.009121067,0.00009721516,0.00004052099,0.007598336],"study_design_scores_gemma":[0.7804674,0.03509977,0.1785004,0.0000668242,0.001319415,0.000004963076,0.0002869449,0.0004901248,0.003617811,0.000009647759,0.0000530933,0.00008365556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936991,0.001006724,0.000006689354,0.001666732,0.0001431507,0.003368469,0.000006342621,0.00001021965,0.00009261422],"genre_scores_gemma":[0.9989315,0.0004946194,0.00005597158,0.0002654597,0.0001015036,0.000132024,0.000002077782,0.00001251233,0.000004328934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1553988,"threshold_uncertainty_score":0.4027741,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2145280166","doi":"10.1016/s1470-2045(10)70218-7","title":"Definition and classification of cancer cachexia: an international consensus","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":5631,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Cachexia; Consensus conference; Cancer cachexia; Cancer; Intensive care medicine; Medicine; Political science; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.5331106926091742,"gpt":0.5308219039922553,"spread":0.002288788616918946,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004432893,0.0001017212,0.0008905245,0.00008607846,0.00003677118,0.000003143729,0.000101236,0.0002077547,0.0001682332],"category_scores_gemma":[0.00004658432,0.00006636501,0.00005418075,0.0000635882,0.0001666645,0.00001384449,0.00002332954,0.0003349393,0.00001439754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001482652,"about_ca_system_score_gemma":0.0003491167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007648586,"about_ca_topic_score_gemma":0.00009393711,"domain_scores_codex":[0.9990771,0.000223573,0.0003551404,0.0001543823,0.00006730385,0.000122475],"domain_scores_gemma":[0.9991025,0.000161511,0.0003724775,0.0002118535,0.00009663896,0.00005506115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001217287,0.0001063172,0.0004563017,0.007180629,0.0001039009,0.000006284562,0.0001578172,6.071127e-9,0.000006217901,0.03815192,0.002074437,0.9516345],"study_design_scores_gemma":[0.0006951925,0.00014237,0.002341274,0.002269749,0.0004176465,0.0001975483,0.00002840283,0.00000620015,5.246782e-7,0.001023364,0.9928219,0.00005579307],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002698267,0.9717596,0.000005259732,0.003491583,0.0004720896,0.0004406834,0.00007875475,0.0000253829,0.02345682],"genre_scores_gemma":[0.0002810332,0.9965236,0.001424871,0.0006702836,0.0007516514,0.0001187305,0.0001421308,0.0000135474,0.00007422235],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9907475,"threshold_uncertainty_score":0.2706287,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127424726","doi":"10.1016/s1470-2045(08)70153-0","title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3195,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Sarcopenic obesity; Sarcopenia; Obesity; Body mass index; Internal medicine; Geriatric oncology; Population; Hazard ratio; Cancer; Gastroenterology; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.09781448145996925,"gpt":0.4135071674502254,"spread":0.3156926859902562,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005971654,0.00004566558,0.0002789426,0.00003019461,0.00006326094,8.256778e-7,0.00006784423,0.0000217312,0.000004614448],"category_scores_gemma":[0.000187536,0.00002591366,0.00001362456,0.0000911734,0.000194373,0.00001629363,0.00002337629,0.0001947619,1.798645e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003556452,"about_ca_system_score_gemma":0.0001710745,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004863274,"about_ca_topic_score_gemma":0.0001821279,"domain_scores_codex":[0.9991001,0.0002976836,0.0003109749,0.000106362,0.00008649785,0.00009836476],"domain_scores_gemma":[0.9991504,0.0003364395,0.0001988589,0.00019794,0.00007895042,0.00003739014],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005496426,0.0008232162,0.9982071,0.00008484687,0.000003209867,0.000001283718,0.0001032043,0.000002171978,0.00001170573,0.000031602,0.00003504889,0.000146989],"study_design_scores_gemma":[0.004801453,0.001923434,0.9929373,0.0001540773,0.0000325189,0.00001591956,0.00003458804,0.00001643216,0.000005110482,0.00004527225,0.00001222669,0.00002161428],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968641,0.00004573888,0.000007145289,0.002310636,0.00001343799,0.0006947115,0.000007794691,0.000005137411,0.00005130735],"genre_scores_gemma":[0.9985636,0.00001438003,0.0005405904,0.0008305276,0.00002898153,0.00001358163,0.00000127654,0.000003516024,0.000003557562],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005269726,"threshold_uncertainty_score":0.1056728,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2486629951","doi":"10.1016/s1470-2045(16)30206-6","title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2995,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"","keywords":"Multiple myeloma; Minimal residual disease; Medicine; Bone marrow; Myeloma protein; Clinical trial; Disease; Oncology; Monoclonal; Internal medicine; Monoclonal antibody; Immunology; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.1849845355372984,"gpt":0.4731506599377273,"spread":0.2881661244004289,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002133735,0.0004067827,0.001870439,0.000315903,0.0001335997,0.00004748845,0.000361507,0.000285648,0.0001241684],"category_scores_gemma":[0.001851552,0.0002344533,0.0002290384,0.0001300295,0.0003610278,0.00003178114,0.0002989687,0.0005151417,0.0000265499],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008343941,"about_ca_system_score_gemma":0.001063542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001475625,"about_ca_topic_score_gemma":0.0000604884,"domain_scores_codex":[0.9961369,0.001536417,0.0006693133,0.0006260934,0.0003247905,0.0007064535],"domain_scores_gemma":[0.9920589,0.006709743,0.0003040784,0.0005457985,0.00008561104,0.0002958274],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02349372,0.0003069696,0.003223959,0.002267292,0.0005630242,0.001824998,0.00007575133,3.189656e-8,0.00004428211,0.0002341926,0.00292003,0.9650458],"study_design_scores_gemma":[0.009628695,0.0007584005,0.04347287,0.005185096,0.0003350485,0.0003392057,0.00003231898,0.00008015893,9.228783e-7,0.000101767,0.9398462,0.0002193752],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01412162,0.9613917,0.00004581392,0.01486226,0.0009585162,0.005429416,0.001496299,0.00008896026,0.001605362],"genre_scores_gemma":[0.01346769,0.9759623,0.005011596,0.0002617118,0.002030201,0.001880135,0.0004590807,0.00008205197,0.000845173],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9648263,"threshold_uncertainty_score":0.9560728,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2112121482","doi":"10.1016/s1470-2045(15)70076-8","title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2666,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Open label; Medicine; Nivolumab; Oncology; Chemotherapy; Internal medicine; Ipilimumab; Randomized controlled trial; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.05803676378711036,"gpt":0.3752254400827541,"spread":0.3171886762956437,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008499426,0.0003240201,0.001726893,0.0000841798,0.00006261166,0.00004530974,0.0003079918,0.0001571798,0.0001433345],"category_scores_gemma":[0.00007141629,0.0001736317,0.00009712103,0.0002495496,0.0002294518,0.0001270311,0.00004423072,0.0001806373,0.00001605522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007469158,"about_ca_system_score_gemma":0.000615879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001321132,"about_ca_topic_score_gemma":0.0002011851,"domain_scores_codex":[0.9978956,0.0004020402,0.0005200137,0.0003873867,0.0002708459,0.0005241061],"domain_scores_gemma":[0.9986183,0.0002262894,0.0003233342,0.0005623119,0.0001367393,0.0001330177],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9294716,0.005111363,0.001959539,0.00001318586,0.0008096154,0.00007856489,0.000819838,0.000001611167,0.0002648302,0.000005621738,0.0008322676,0.06063199],"study_design_scores_gemma":[0.905581,0.05465214,0.002115391,0.00007474726,0.0002272193,0.000008712235,0.00009579988,0.00006879399,0.000374184,0.00001079027,0.03658772,0.0002035295],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982309,0.001048072,0.000006048208,0.003636876,0.0005850302,0.009512851,0.00002825955,0.00004919258,0.002824606],"genre_scores_gemma":[0.9936758,0.0004616587,0.0004728165,0.001460422,0.0004182822,0.002877564,0.00006029124,0.00004996131,0.0005231707],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06042846,"threshold_uncertainty_score":0.7080494,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2805592007","doi":"10.1016/s1470-2045(18)30351-6","title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2536,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Sorafenib; Internal medicine; Clinical endpoint; Hepatocellular carcinoma; Adverse effect; Response Evaluation Criteria in Solid Tumors; Population; Oncology; Discontinuation; Clinical trial; Phases of clinical research; Surgery; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.07727556601902094,"gpt":0.3280706321942589,"spread":0.2507950661752379,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006522154,0.0004755211,0.001605491,0.0001571592,0.0002100709,0.00005261987,0.0005193806,0.0002228921,0.0001792788],"category_scores_gemma":[0.00006857004,0.0002637832,0.00008132695,0.0005639262,0.0004077969,0.0001785301,0.0001363712,0.0004176062,0.00008097912],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003565189,"about_ca_system_score_gemma":0.0005994593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003409635,"about_ca_topic_score_gemma":0.0002724214,"domain_scores_codex":[0.9970579,0.0004834506,0.0005541908,0.0006711577,0.0003594835,0.0008737895],"domain_scores_gemma":[0.9980447,0.0002077508,0.0003283086,0.000919019,0.0002603237,0.0002399122],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5517698,0.003345056,0.4360516,0.00003854976,0.0001993847,0.0004277666,0.0006207214,2.838657e-7,0.0001672977,0.00001687184,0.0002803377,0.007082351],"study_design_scores_gemma":[0.9003534,0.06457949,0.02695294,0.000150611,0.0007274512,0.00005724617,0.00005168627,0.00135801,0.001614832,0.00002328879,0.003768486,0.0003625962],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837359,0.0001898708,0.0000520611,0.0008394131,0.0001212976,0.01018509,0.00002685466,0.00007721362,0.004772302],"genre_scores_gemma":[0.995565,0.0000419341,0.001170686,0.0006509269,0.00051266,0.001356735,0.00024824,0.00008142297,0.0003724127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4090987,"threshold_uncertainty_score":0.9999815,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3083986479","doi":"10.1016/s1470-2045(20)30445-9","title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2492,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Cohort; Mesothelioma; Biomarker; Clinical endpoint; Prospective cohort study; Cancer; Progressive disease; Disease; Immunotherapy; Pathology; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.03122114611269687,"gpt":0.3549706413578277,"spread":0.3237494952451308,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003858868,0.0001940642,0.001109758,0.0001183744,0.00006192654,0.00001107944,0.0002973652,0.00005985467,0.00004432455],"category_scores_gemma":[0.0001052071,0.00008896064,0.00005692992,0.00137166,0.0001775989,0.00008706557,0.0000582186,0.0001922041,6.040575e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003845049,"about_ca_system_score_gemma":0.0002772972,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004974001,"about_ca_topic_score_gemma":0.001790371,"domain_scores_codex":[0.9982575,0.0003220151,0.0004229108,0.0002966519,0.0004636568,0.0002372351],"domain_scores_gemma":[0.9983468,0.0002301708,0.0007405409,0.0002887756,0.0003498682,0.00004385175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09481508,0.002597779,0.8913,0.00001721603,0.005599875,0.00001360054,0.002920771,0.0003636715,0.001515355,0.000003960829,0.00003921138,0.0008134344],"study_design_scores_gemma":[0.08969664,0.01016329,0.895515,0.0000436441,0.002315455,0.000001899529,0.0009282193,0.0006623731,0.0005366306,0.000002843388,0.00002375492,0.0001102817],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936353,0.00002425659,0.000014342,0.003369646,0.0000207797,0.002509847,0.0001104518,0.00001585204,0.0002995427],"genre_scores_gemma":[0.9990866,0.000005953128,0.0001958037,0.0003900555,0.00002211765,0.000119022,0.00005353283,0.00002024581,0.0001066475],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007565511,"threshold_uncertainty_score":0.3627709,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2592144107","doi":"10.1016/s1470-2045(17)30074-8","title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2408,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Guideline; Clinical trial; Medicine; Medical physics; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Cancer; Intensive care medicine; Oncology; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.8623875272759276,"gpt":0.6325735133841923,"spread":0.2298140138917353,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02059164,0.0004207717,0.005353143,0.0001905934,0.0002093897,0.00008925449,0.0006282348,0.0006114243,0.00003331043],"category_scores_gemma":[0.02540172,0.0002423027,0.0009510769,0.0001542576,0.0002202904,0.00005381668,0.0000633879,0.0003454103,0.000005377456],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005018814,"about_ca_system_score_gemma":0.001684447,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009149541,"about_ca_topic_score_gemma":0.0001046674,"domain_scores_codex":[0.9953505,0.00161788,0.001952556,0.000417611,0.0001223027,0.0005391888],"domain_scores_gemma":[0.9759513,0.02070364,0.001631789,0.00121874,0.000450982,0.00004354977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03372974,0.00006217045,0.000004426758,0.00388851,0.000519349,0.0000119247,0.00006573396,8.306854e-8,0.0001850677,0.00001535452,0.02000875,0.9415089],"study_design_scores_gemma":[0.008306851,0.001282534,0.00004781538,0.008308829,0.001392956,0.0001796262,0.00001631393,0.00004180775,0.000006531438,0.000137892,0.9800229,0.0002559164],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004523365,0.9860235,0.0002421745,0.005322613,0.001600403,0.006041316,0.0005378904,0.00005014982,0.0001366653],"genre_scores_gemma":[0.000002018064,0.9689936,0.02067439,0.002767974,0.003176367,0.002136356,0.0001249131,0.000100487,0.002023891],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9600142,"threshold_uncertainty_score":0.9880818,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2123591186","doi":"10.1016/s1470-2045(11)70336-9","title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2358,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Pertuzumab; Trastuzumab; Docetaxel; Medicine; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Population; Chemotherapy; Clinical trial; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.06039123479763487,"gpt":0.3881995916148677,"spread":0.3278083568172329,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001226815,0.0002816015,0.001382688,0.00007187853,0.00009425821,0.00002452541,0.0003779725,0.0001664881,0.0005342118],"category_scores_gemma":[0.0001825133,0.0001635873,0.00002091085,0.0002643974,0.0007477471,0.0001424206,0.0002201352,0.0005703571,0.000004116294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006944237,"about_ca_system_score_gemma":0.001535974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00152276,"about_ca_topic_score_gemma":0.001932494,"domain_scores_codex":[0.9973057,0.0006045143,0.0005869674,0.0004797016,0.0003087269,0.000714398],"domain_scores_gemma":[0.9980726,0.0007802699,0.0002570654,0.0004289836,0.00018015,0.0002809792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7835139,0.001475786,0.001224555,0.0001293732,0.0002386719,0.0003371207,0.01119351,0.000004279875,0.0008541475,0.00003390334,0.00008658748,0.2009082],"study_design_scores_gemma":[0.9200645,0.02174518,0.05239725,0.000736895,0.0001385047,0.0003295829,0.001626245,0.0002367179,0.0003105945,0.00002756332,0.002144502,0.0002424681],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899136,0.0006241543,0.00003567335,0.001607077,0.00009459064,0.00578293,0.00009619097,0.00002580127,0.001819965],"genre_scores_gemma":[0.9948663,0.002079924,0.001020581,0.0005565817,0.0002130566,0.0009848844,0.000004298931,0.00005015329,0.0002241826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2006657,"threshold_uncertainty_score":0.6670897,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2160305510","doi":"10.1016/s1470-2045(06)70664-7","title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2085,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Rituximab; CHOP; Internal medicine; Vincristine; International Prognostic Index; Chemotherapy; Clinical endpoint; Diffuse large B-cell lymphoma; Lymphoma; Oncology; Prednisone; Surgery; Cyclophosphamide; Gastroenterology; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.01156893336735901,"gpt":0.2673967495049783,"spread":0.2558278161376193,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001154473,0.0005698652,0.002038391,0.0001250528,0.0002144192,0.00008894791,0.0005683306,0.0003204145,0.000227789],"category_scores_gemma":[0.00007045313,0.0002982483,0.0004264909,0.0002791883,0.0002474453,0.0001069456,0.00006523229,0.0002893104,0.00003821738],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001518935,"about_ca_system_score_gemma":0.0003287251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001205254,"about_ca_topic_score_gemma":0.00120423,"domain_scores_codex":[0.9962612,0.0006201012,0.000927905,0.0006544058,0.0007110225,0.0008253797],"domain_scores_gemma":[0.9970536,0.001397897,0.0006121207,0.0006840708,0.0001370823,0.0001152068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9362409,0.03976098,0.009694339,0.00001200509,0.001043807,0.00004185366,0.0005354779,0.000002468391,0.00006257374,0.0001356507,0.00851318,0.003956763],"study_design_scores_gemma":[0.9374016,0.005543079,0.01582389,0.00003368944,0.0004548167,0.00001478503,0.00008266584,0.0002257029,0.000108988,0.00004399001,0.03997402,0.0002928057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9734367,0.0005853328,0.00003927503,0.006485387,0.002389621,0.01119837,0.00008594783,0.0001003844,0.005678972],"genre_scores_gemma":[0.9877065,0.0006240792,0.0001726956,0.003375192,0.002035218,0.004848215,0.0003129202,0.0000879435,0.0008372306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0342179,"threshold_uncertainty_score":0.999947,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1968899146","doi":"10.1016/s1470-2045(14)71207-0","title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2007,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Carboplatin; Medicine; Cetuximab; Paclitaxel; Oncology; Radiation therapy; Stage (stratigraphy); Internal medicine; Lung cancer; Chemotherapy; Nuclear medicine; Cancer; Cisplatin; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04436868744910295,"gpt":0.3865590085254279,"spread":0.342190321076325,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005145323,0.0005180626,0.001642302,0.0000697663,0.000196636,0.00008745523,0.0001524445,0.0001012608,0.00007010727],"category_scores_gemma":[0.0000523536,0.0002381034,0.00004876745,0.0001635939,0.0002828927,0.0001960071,0.00004302536,0.0002850102,8.359664e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001713977,"about_ca_system_score_gemma":0.002489876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002213754,"about_ca_topic_score_gemma":0.006682937,"domain_scores_codex":[0.9975653,0.0002398177,0.000463991,0.0005702896,0.0005221743,0.0006384876],"domain_scores_gemma":[0.9973685,0.0008055219,0.0005338754,0.0004651413,0.0004890216,0.0003379287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8578196,0.002856647,0.1231481,0.0001703135,0.002316851,0.00008350664,0.00714884,0.0001986475,0.00002723147,0.00002171554,0.002824902,0.00338366],"study_design_scores_gemma":[0.905369,0.07870068,0.00173956,0.0001815426,0.002553957,0.00001558265,0.001416067,0.001309369,0.0002589082,0.000001044939,0.008044799,0.0004094947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843884,0.0003902497,0.001200357,0.0004099006,0.0008436175,0.01147713,0.001106713,0.00006416257,0.0001195342],"genre_scores_gemma":[0.9942003,0.0002766733,0.001084189,0.0003018894,0.0006224943,0.002821832,0.0002874432,0.00007997087,0.00032514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1214086,"threshold_uncertainty_score":0.9709577,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151730005","doi":"10.1016/s1470-2045(09)70311-0","title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1974,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Cetuximab; Head and neck cancer; Clinical endpoint; Radiation therapy; Rash; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Randomized controlled trial; Surgery; Cancer; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.154146220113929,"gpt":0.4342346987075292,"spread":0.2800884785936002,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009607497,0.0002637849,0.001712858,0.00005524481,0.0002395177,0.00002877659,0.0001938948,0.0001851438,0.00001836945],"category_scores_gemma":[0.00027571,0.0001870078,0.0000528346,0.0001122693,0.0002015705,0.0001376977,0.00007971573,0.000291811,8.041395e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000149006,"about_ca_system_score_gemma":0.0003240277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002372828,"about_ca_topic_score_gemma":0.0004552603,"domain_scores_codex":[0.9980993,0.0002891556,0.0004244739,0.0005779848,0.0001991524,0.0004099743],"domain_scores_gemma":[0.9974861,0.001549241,0.0002135071,0.0005171639,0.00008105977,0.0001529977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6506714,0.0005187,0.01251183,0.000133094,0.0009378187,0.00002968599,0.00215286,0.000003062413,0.01015675,0.0005295189,0.005852334,0.316503],"study_design_scores_gemma":[0.8684928,0.006928365,0.07174842,0.0001261075,0.0004820503,0.00001494103,0.0002106367,0.00100423,0.0001026168,0.0009179015,0.0496812,0.0002907321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9565917,0.005835721,0.0004907816,0.03327427,0.0004044484,0.0024158,0.0004979636,0.00006442635,0.0004249416],"genre_scores_gemma":[0.9754176,0.01600167,0.002881608,0.001692827,0.003281046,0.0001889933,0.00039571,0.00003953093,0.0001010108],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3162123,"threshold_uncertainty_score":0.7625957,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2131719808","doi":"10.1016/s1470-2045(10)70207-2","title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1919,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saint John Regional Hospital; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Axillary Lymph Node Dissection; Sentinel lymph node; Breast cancer; Lumpectomy; Mastectomy; Surgery; Axilla; Sentinel node; Lymph node; Clinical endpoint; Randomized controlled trial; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02129551545244373,"gpt":0.3209903072835433,"spread":0.2996947918310996,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006140416,0.0003188209,0.0006439848,0.00003443286,0.0003090357,0.00003956344,0.0003393223,0.0002257026,0.0001000689],"category_scores_gemma":[0.0001431263,0.0001793361,0.0001233068,0.0001582262,0.0004943406,0.0000174865,0.0001238654,0.0003677511,0.000005683277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001659343,"about_ca_system_score_gemma":0.0003132531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001839465,"about_ca_topic_score_gemma":0.003829614,"domain_scores_codex":[0.9976698,0.0005652051,0.0004655413,0.0005700163,0.0003010724,0.0004283191],"domain_scores_gemma":[0.9983297,0.0005012383,0.0003831463,0.0004668921,0.0002497312,0.00006928152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4295141,0.0009080696,0.5647764,0.000008496728,0.0006281505,0.000006238852,0.0002440585,0.0001420968,0.002608995,0.00002459567,0.0005783524,0.000560439],"study_design_scores_gemma":[0.3148481,0.0003454618,0.6830004,0.00003743047,0.0001631387,0.00001799879,0.0001134973,0.00009738152,0.0004026331,0.00006505499,0.0007000137,0.0002088513],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931682,0.00005636858,0.0001283484,0.003833825,0.0009757088,0.0008695625,0.0005353298,0.00002647446,0.0004061264],"genre_scores_gemma":[0.9963081,0.0001311619,0.0001786979,0.0007440012,0.001517263,0.000445577,0.0005900569,0.0000353057,0.0000498328],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1182241,"threshold_uncertainty_score":0.7313116,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2737389832","doi":"10.1016/s1470-2045(17)30469-2","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1863,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Olaparib; Medicine; BRCA mutation; Ovarian cancer; Internal medicine; Oncology; Placebo; PARP inhibitor; Clinical endpoint; Population; Randomized controlled trial; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.05211112076256093,"gpt":0.3733703096465478,"spread":0.3212591888839869,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001682879,0.0003670365,0.001584582,0.0001484887,0.0004386177,0.0000924792,0.0002797686,0.0002910678,0.0001850112],"category_scores_gemma":[0.0003290029,0.0002299431,0.000100233,0.0001505273,0.0005417186,0.0002401191,0.00004959268,0.0006896918,0.00001844471],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004338318,"about_ca_system_score_gemma":0.0006244626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008258184,"about_ca_topic_score_gemma":0.0007803391,"domain_scores_codex":[0.9973008,0.0004661643,0.0006501529,0.0005628604,0.0003848895,0.0006351458],"domain_scores_gemma":[0.9971354,0.0006848363,0.0009266972,0.000809251,0.0002961268,0.0001477079],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9785604,0.0007137279,0.001897945,0.00002032379,0.0004332087,0.0001393949,0.001549875,0.00003959517,0.0006978901,0.0004580743,0.001167218,0.01432233],"study_design_scores_gemma":[0.9805862,0.005681535,0.006925271,0.0002154181,0.0001562721,0.0000727819,0.0001087261,0.0002634831,0.0007082772,0.0003432124,0.004665223,0.00027359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710769,0.0002094362,0.0001065273,0.01176316,0.000689771,0.008455561,0.00005653547,0.00006344953,0.007578632],"genre_scores_gemma":[0.9910946,0.0006242977,0.0003184927,0.003515606,0.001021563,0.002676675,0.00005808782,0.00005352461,0.0006371356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02001769,"threshold_uncertainty_score":0.9376807,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2290950904","doi":"10.1016/s1470-2045(15)00613-0","title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1822,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; University of Calgary","funders":"University of California, Los Angeles; Novartis; Daiichi-Sankyo; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; U.S. Department of Defense","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Placebo; Internal medicine; Oncology; Gynecology; Cancer; Breast cancer; Estrogen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.1235990477317247,"gpt":0.4149209742192354,"spread":0.2913219264875107,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005927148,0.0005879899,0.00359845,0.0002012627,0.0001604418,0.00001360908,0.0004184213,0.0001275011,0.0002093901],"category_scores_gemma":[0.0001207619,0.0002531136,0.001133346,0.0005139093,0.0008510839,0.00009407445,0.00003016873,0.0001654767,0.000002385966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001032316,"about_ca_system_score_gemma":0.0009422986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003933841,"about_ca_topic_score_gemma":0.0005001402,"domain_scores_codex":[0.9962571,0.0008829798,0.001001024,0.0005819036,0.0005457136,0.0007312445],"domain_scores_gemma":[0.9924019,0.004889149,0.001384442,0.0008009481,0.0003689285,0.0001546299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9266046,0.002847274,0.0000849642,0.00004482828,0.01823892,0.00001935493,0.00239656,0.0005480421,0.009399512,0.0001114962,0.00003489606,0.03966961],"study_design_scores_gemma":[0.9468176,0.01456339,0.00107265,0.0001402238,0.008859046,0.00002253284,0.0004638585,0.0006455318,0.02638,0.00003687253,0.0007420401,0.0002562884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648197,0.002174971,0.0005811652,0.007998017,0.0006042545,0.02210978,0.001549025,0.0000544999,0.0001086103],"genre_scores_gemma":[0.9884078,0.002632072,0.0005891541,0.000171765,0.0005243631,0.007307405,0.00006232344,0.00005784004,0.0002472751],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03941332,"threshold_uncertainty_score":0.9999921,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2946386783","doi":"10.1016/s1470-2045(19)30167-6","title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1681,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"William Osler Health System","funders":"F. Hoffmann-La Roche","keywords":"Carboplatin; Medicine; Paclitaxel; Atezolizumab; Chemotherapy; Oncology; Nab-paclitaxel; Open label; Internal medicine; Lung cancer; Cisplatin; Cancer; Randomized controlled trial; Nivolumab; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.04848363890646765,"gpt":0.3745263839184664,"spread":0.3260427450119987,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008126488,0.0005305943,0.002057799,0.000142406,0.0001496843,0.00006186465,0.0004141528,0.0001651716,0.0003009691],"category_scores_gemma":[0.00002088924,0.0003147473,0.0001289025,0.0004013135,0.0001689769,0.0001125532,0.00003286235,0.0002667205,0.000009096651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001669292,"about_ca_system_score_gemma":0.001256861,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00464751,"about_ca_topic_score_gemma":0.006687745,"domain_scores_codex":[0.9974245,0.0002184191,0.000713366,0.0006279192,0.0002871266,0.0007285972],"domain_scores_gemma":[0.9975975,0.0008134393,0.0006043657,0.0006867169,0.0001685544,0.0001294434],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9677392,0.006894242,0.001005181,0.0003043417,0.001308195,0.00006326105,0.00610342,0.0003058375,0.005830334,0.000008782099,0.0007205427,0.009716677],"study_design_scores_gemma":[0.926024,0.03383809,0.0005579339,0.0002751585,0.0006166384,0.0000562704,0.000587897,0.02512565,0.004592743,0.00001705764,0.007892759,0.000415774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9676853,0.001136664,0.0005747847,0.007206224,0.0003377473,0.02202023,0.00008264299,0.00004875455,0.0009075878],"genre_scores_gemma":[0.9867935,0.001625546,0.0022427,0.002967075,0.0002800841,0.004031883,0.0001960679,0.0001121823,0.001750931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04171515,"threshold_uncertainty_score":0.9999304,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2132870547","doi":"10.1016/s1470-2045(14)71173-8","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1580,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Pemetrexed; Lung cancer; Internal medicine; Adenocarcinoma; Lung; Gemcitabine; Chemotherapy; Population; Gastroenterology; Oncology; Cisplatin; Surgery; Gefitinib; Epidermal growth factor receptor; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1710050663165039,"gpt":0.4951860196022361,"spread":0.3241809532857323,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001940474,0.0002310315,0.001719452,0.0001567495,0.0001091328,0.00002635559,0.0002478204,0.0001143298,0.0001921946],"category_scores_gemma":[0.0009088597,0.0001580474,0.0002067423,0.0002964599,0.0001497884,0.0001038509,0.00004832793,0.0001361102,0.000001883236],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003370136,"about_ca_system_score_gemma":0.0006911011,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009631529,"about_ca_topic_score_gemma":0.0003780268,"domain_scores_codex":[0.997747,0.0005902059,0.0006582255,0.0004483922,0.0002613775,0.0002948028],"domain_scores_gemma":[0.9928087,0.005467508,0.0005859752,0.0007228797,0.0002635863,0.00015133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6963817,0.002798289,0.1101823,0.0003810475,0.08172291,0.0002253592,0.01956422,0.005411376,0.00422535,0.002161017,0.04137653,0.03556987],"study_design_scores_gemma":[0.6607468,0.001862386,0.0232797,0.00007401693,0.03959235,0.000006313746,0.0008956725,0.269698,0.0009662139,0.0002645481,0.002319049,0.0002949757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9628026,0.004286501,0.01524548,0.006349942,0.000820927,0.003638968,0.004468661,0.00005839936,0.002328557],"genre_scores_gemma":[0.9868315,0.000106595,0.004777963,0.0008298031,0.0008806532,0.0002107292,0.006212393,0.0000326443,0.0001177421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2642866,"threshold_uncertainty_score":0.6444986,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2145426305","doi":"10.1016/s1470-2045(05)70101-7","title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1580,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Placebo; Medicine; Double blind; Virus-like particle; Human papillomavirus; Internal medicine; Virology; Recombinant DNA; Alternative medicine; Pathology; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.08610090242738114,"gpt":0.4192445002258663,"spread":0.3331435977984851,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002735348,0.0002732978,0.001513,0.0001217608,0.000364465,0.00004292727,0.0002388816,0.0001736502,0.003590281],"category_scores_gemma":[0.0004258708,0.000172199,0.0001359524,0.000273446,0.0001582881,0.00009181967,0.0001567479,0.0008035593,0.00004955073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006735886,"about_ca_system_score_gemma":0.0002432552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003303721,"about_ca_topic_score_gemma":0.005076414,"domain_scores_codex":[0.9966962,0.0008571071,0.0007103246,0.000452631,0.0003822292,0.0009014534],"domain_scores_gemma":[0.997925,0.0009865199,0.0001847763,0.0004891003,0.0001028766,0.0003116551],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9653571,0.003835834,0.0005439753,0.00009779527,0.0001771768,0.00006305576,0.003868899,0.00002343615,0.006055018,0.00009483786,0.0004762968,0.01940662],"study_design_scores_gemma":[0.9797681,0.005810794,0.002031472,0.00001466196,0.0002593415,0.00002901614,0.0004104735,0.0008579771,0.00123538,0.0000623272,0.009327931,0.0001925281],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795076,0.0009853895,0.000004335472,0.007661029,0.0002066611,0.006176998,0.000005769403,0.00006837557,0.00538381],"genre_scores_gemma":[0.9943287,0.0002695606,0.00003570645,0.000924065,0.001809877,0.001299093,0.00001209599,0.00003193742,0.001288984],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0192141,"threshold_uncertainty_score":0.9973206,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165693726","doi":"10.1016/s1470-2045(08)70179-7","title":"Cancer survival in five continents: a worldwide population-based study (CONCORD)","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1469,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Relative survival; Medicine; Demography; Cancer; Population; Cancer registry; Breast cancer; Prostate cancer; Colorectal cancer; Survival rate; Survival analysis; Gerontology; Oncology; Internal medicine; Environmental health","retraction":null,"screen_n_in":null,"score":{"opus":0.1847457346792045,"gpt":0.4231636361772668,"spread":0.2384179014980623,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005831097,0.0001259867,0.000602332,0.0000717855,0.00009839908,0.000005269249,0.0001880339,0.00006762751,0.0002018163],"category_scores_gemma":[0.0001919921,0.00008720601,0.00005408001,0.0003202873,0.00006493078,0.00004691954,0.00003901365,0.0003198849,0.00002468311],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003977562,"about_ca_system_score_gemma":0.0003392507,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02221522,"about_ca_topic_score_gemma":0.03952267,"domain_scores_codex":[0.998609,0.0002617261,0.0002994591,0.0002292824,0.0002515732,0.0003489613],"domain_scores_gemma":[0.9991468,0.0002766525,0.0001162608,0.0003081812,0.00008782571,0.00006427979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001197516,0.0001777489,0.9930336,0.000008152932,0.00003583966,0.0003151346,0.0007716067,0.0004523151,0.00003777941,0.00004843041,0.002351249,0.001570625],"study_design_scores_gemma":[0.005853279,0.0005533186,0.9850866,0.0000563404,0.00004883837,0.0000221343,0.000768797,0.0003893056,0.00001314583,0.00005528068,0.007058591,0.00009433536],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841825,0.0003021788,0.00002610357,0.01075236,0.0003718847,0.0005945395,0.0000082643,0.00004772414,0.00371449],"genre_scores_gemma":[0.9929742,0.00004826409,0.0001554366,0.005391843,0.0006304714,0.0001390324,0.00001305417,0.00001195666,0.0006357429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01730744,"threshold_uncertainty_score":0.9842959,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2896600825","doi":"10.1016/s1470-2045(18)30700-9","title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1409,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Internal medicine; Oncology; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.059457284228469,"gpt":0.3855917897477813,"spread":0.3261345055193123,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001466869,0.0004203306,0.002274485,0.0002232364,0.0001463984,0.00001766271,0.0005287401,0.0003273101,0.0011513],"category_scores_gemma":[0.0006880736,0.0002740658,0.0003541765,0.0005495101,0.000811893,0.0001312383,0.0001347581,0.0004628996,0.00009868885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008381379,"about_ca_system_score_gemma":0.0008374284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000670462,"about_ca_topic_score_gemma":0.003888741,"domain_scores_codex":[0.9964208,0.0005532781,0.001154732,0.0005568044,0.0004357318,0.0008786446],"domain_scores_gemma":[0.9968739,0.001162812,0.0005888959,0.00104268,0.0001895754,0.0001421445],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9536278,0.001443665,0.0004076472,0.00008974916,0.0007904752,0.0001135082,0.001876405,0.000004915042,0.008165564,0.00003213917,0.00157358,0.03187456],"study_design_scores_gemma":[0.9513123,0.01552613,0.002623274,0.0001233043,0.0004007438,0.00005105363,0.001137759,0.0005143405,0.004532529,0.00003452764,0.02342135,0.0003226896],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870612,0.0007673303,0.0000448051,0.00282389,0.002373919,0.003143369,0.00007041116,0.0001149987,0.003600048],"genre_scores_gemma":[0.9939461,0.0009182284,0.001097163,0.0008566226,0.001084869,0.0002585417,0.00004600564,0.00006444114,0.001728002],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03155187,"threshold_uncertainty_score":0.9999712,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2113344831","doi":"10.1016/s1470-2045(09)70314-6","title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1405,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genomic Health; U.S. Department of Health and Human Services","keywords":"Tamoxifen; Medicine; Internal medicine; Breast cancer; Oncology; Hazard ratio; Proportional hazards model; Anthracycline; Chemotherapy; Cyclophosphamide; Retrospective cohort study; Gynecology; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.008274236675616017,"gpt":0.2673977770089922,"spread":0.2591235403333762,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004154271,0.0002294412,0.0007942038,0.00007197369,0.00007383073,0.000005839523,0.0002246133,0.0001194587,0.000009391318],"category_scores_gemma":[0.00007666785,0.0001293638,0.00008102765,0.0004984828,0.0004415424,0.00000542608,0.00006096897,0.0001652507,1.591883e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002630986,"about_ca_system_score_gemma":0.0002112067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001145933,"about_ca_topic_score_gemma":0.0001473169,"domain_scores_codex":[0.9983449,0.0004955434,0.0002621734,0.0004030182,0.0001855396,0.0003088343],"domain_scores_gemma":[0.9989283,0.0001747312,0.0003585888,0.0003236714,0.000174436,0.00004028887],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6287138,0.001449358,0.2855937,0.00001830492,0.007420266,0.000005826934,0.005118176,0.001012942,0.06529313,0.0002019041,0.00007002119,0.005102526],"study_design_scores_gemma":[0.05639826,0.00485297,0.9221349,0.00007077165,0.000714069,0.00001118858,0.000187184,0.00006902451,0.01535723,0.00006433223,0.000007987542,0.0001320592],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951506,0.0003544432,0.00004826474,0.001952397,0.00006342032,0.001200244,0.0009142787,0.000005245936,0.0003111639],"genre_scores_gemma":[0.9984028,0.0003634302,0.00009396353,0.0005853605,0.0001600455,0.0003285193,0.00004672119,0.00001202919,0.000007156657],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6365412,"threshold_uncertainty_score":0.5275304,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168108459","doi":"10.1016/s1470-2045(12)70379-0","title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1387,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"Janssen Research and Development; UCLH Biomedical Research Centre","keywords":"Abiraterone acetate; Medicine; Placebo; Prednisone; Prostate cancer; Clinical endpoint; Interim analysis; Internal medicine; Enzalutamide; Docetaxel; Population; Oncology; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.187337688920738,"gpt":0.4545089135261337,"spread":0.2671712246053957,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001641254,0.0002592815,0.00215015,0.0001613824,0.0001578604,0.000013556,0.0001976042,0.0000566079,0.0001374977],"category_scores_gemma":[0.00005238489,0.0001173223,0.0004438003,0.0004423437,0.0002506557,0.00006796759,0.00003532356,0.0001037906,0.000001858205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004198121,"about_ca_system_score_gemma":0.0006199691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007652444,"about_ca_topic_score_gemma":0.001467372,"domain_scores_codex":[0.9974428,0.0006404388,0.0007126536,0.0002495397,0.0003933646,0.0005612333],"domain_scores_gemma":[0.9976661,0.0008552834,0.0005555762,0.0005318313,0.0002778269,0.0001134002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9420376,0.005636428,0.01478946,0.0001301817,0.01688264,0.0000145627,0.006387701,0.0005752128,0.01089463,0.0001125105,0.000158522,0.002380588],"study_design_scores_gemma":[0.9551365,0.00749364,0.008343978,0.00002556125,0.01875508,0.000005030901,0.001218721,0.0008365894,0.006760625,0.00003229629,0.001262072,0.000129909],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837747,0.002015833,0.0000366939,0.002525269,0.0002579911,0.01071882,0.0003864799,0.00001464593,0.0002695927],"genre_scores_gemma":[0.992819,0.0007175906,0.0001205411,0.00005539147,0.0002155359,0.00391535,0.00009635864,0.00002131474,0.002038882],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01309893,"threshold_uncertainty_score":0.4784263,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2753659610","doi":"10.1016/s1470-2045(17)30582-x","title":"Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1382,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Japanese Association of Cardiac Rehabilitation; L'Oreal USA","keywords":"Advance care planning; Delphi method; Delphi; Pooling; Palliative care; Health care; Process (computing); Adaptation (eye); Medicine; Nursing; Process management; Psychology; Medical education; Political science; Computer science; Business","retraction":null,"screen_n_in":null,"score":{"opus":0.5513145969617606,"gpt":0.5722748071410236,"spread":0.02096021017926308,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006711324,0.000188839,0.0009824804,0.00004392767,0.0002418214,0.00002286518,0.0002750252,0.0001706104,0.00000634448],"category_scores_gemma":[0.001401339,0.0001156365,0.0001579578,0.00003547385,0.000108279,0.00003682383,0.00004550336,0.0002584412,0.000002478419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003948399,"about_ca_system_score_gemma":0.0002213503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001420856,"about_ca_topic_score_gemma":0.00005302184,"domain_scores_codex":[0.9986095,0.0004714106,0.0003708214,0.0002432231,0.000105181,0.0001998151],"domain_scores_gemma":[0.9957989,0.002277253,0.001035644,0.0003096597,0.0005382237,0.00004036302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002341549,0.00004876154,0.001360179,0.004000844,0.0007316489,0.000005250724,0.01037363,4.346952e-7,0.000002856103,0.001536077,0.0469017,0.9348044],"study_design_scores_gemma":[0.001529358,0.000417277,0.0001767277,0.002914428,0.0009506453,0.000006977625,0.003390661,0.000003439306,0.000003574001,0.0002795205,0.9902128,0.0001145934],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007586767,0.9692329,0.0001850247,0.005174591,0.0006787544,0.001816096,0.005122562,0.00003200209,0.01768222],"genre_scores_gemma":[0.0003463033,0.9831998,0.003893253,0.000366876,0.001053687,0.0003864442,0.01041676,0.00003609286,0.000300758],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9433111,"threshold_uncertainty_score":0.4715519,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2055346449","doi":"10.1016/s1470-2045(14)71205-7","title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1354,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Placebo; Internal medicine; Oncology; Castration; Urology; Abiraterone; Enzalutamide; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1589090600127682,"gpt":0.4258998720708133,"spread":0.2669908120580451,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002998873,0.0005134636,0.003282598,0.0004817025,0.0001281249,0.00005791506,0.0003629067,0.0001271126,0.0001906786],"category_scores_gemma":[0.00009622835,0.0003006473,0.0002197622,0.001092295,0.0004041253,0.0001752098,0.00008584069,0.0005137865,0.000007720719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00176902,"about_ca_system_score_gemma":0.003078348,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003552231,"about_ca_topic_score_gemma":0.01029028,"domain_scores_codex":[0.995339,0.001137285,0.0009978913,0.0006821157,0.000950179,0.0008935454],"domain_scores_gemma":[0.9970813,0.0007721098,0.0006680258,0.0007054448,0.0004818679,0.0002912504],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9464379,0.002250246,0.002099341,0.0001144304,0.01489309,0.0004695777,0.0174573,0.01376485,0.001599766,0.00002648981,0.0003336929,0.0005533326],"study_design_scores_gemma":[0.9573971,0.01183193,0.001784175,0.00007425837,0.007183235,0.00001247772,0.005685242,0.01481517,0.0007373089,0.00002656291,0.0001560062,0.0002965203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799966,0.001235983,0.00007198528,0.003110346,0.0001606901,0.01328694,0.0001943093,0.00005556865,0.001887591],"genre_scores_gemma":[0.9910275,0.0005633815,0.0002729443,0.00008901483,0.0001833735,0.004745675,0.0001959956,0.0000579407,0.002864144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01177206,"threshold_uncertainty_score":0.9999446,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2070825440","doi":"10.1016/s1470-2045(15)70122-1","title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1255,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Cancer Foundation","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Ipilimumab; Placebo; Medicine; Adjuvant; Oncology; Melanoma; Internal medicine; Stage (stratigraphy); Resection; Surgery; Cancer; Immunotherapy; Cancer research; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1165948738888528,"gpt":0.3704590522131933,"spread":0.2538641783243404,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001809423,0.0002243136,0.001057141,0.0001768358,0.00009942638,0.00001751597,0.0001997765,0.0001769144,0.000573138],"category_scores_gemma":[0.0002133998,0.0001553059,0.0001732823,0.0002233038,0.0002014489,0.00004739583,0.0001274255,0.0004530229,0.0001163515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000363733,"about_ca_system_score_gemma":0.00023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008602751,"about_ca_topic_score_gemma":0.001536388,"domain_scores_codex":[0.9977139,0.0005428843,0.0005977463,0.0003431901,0.0003974586,0.0004047681],"domain_scores_gemma":[0.998109,0.0004381051,0.0004261126,0.0006711239,0.0001635066,0.0001921046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9849662,0.0005832948,0.00002807658,0.00004628712,0.0004598098,0.0002599221,0.0007676188,0.00007321344,0.000379758,0.0003703023,0.005683992,0.006381589],"study_design_scores_gemma":[0.8234566,0.01634382,0.00004151438,0.00001885889,0.0005735339,0.0001194061,0.000604118,0.0004017403,0.0005666841,0.00008511742,0.1576506,0.0001379665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9773476,0.0001813562,0.0005559263,0.001672337,0.003509213,0.003566695,0.00005685278,0.0001147979,0.01299523],"genre_scores_gemma":[0.9937733,0.0001514132,0.000183668,0.0003089532,0.001895573,0.0005057707,0.0000441214,0.00002993171,0.003107213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1615095,"threshold_uncertainty_score":0.633319,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137935883","doi":"10.1016/s1470-2045(09)70262-1","title":"Ki67 in breast cancer: prognostic and predictive potential","year":2010,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1226,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Oncology; Medicine; Pathological; Oestrogen receptor; Internal medicine; Predictive marker; Cancer; Human Epidermal Growth Factor Receptor 2; Gynecology; Progesterone receptor; Bioinformatics; Estrogen receptor; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.0245620792448499,"gpt":0.3433855665218097,"spread":0.3188234872769598,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002226047,0.0003235597,0.001160124,0.00004594952,0.00007993283,0.00001290243,0.0003122331,0.0004976837,0.00001723274],"category_scores_gemma":[0.00003321442,0.0002025249,0.0001183822,0.0000983764,0.0003309244,0.000002036776,0.0003211752,0.0004885424,0.000007527861],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009238767,"about_ca_system_score_gemma":0.0003894578,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001070599,"about_ca_topic_score_gemma":0.0005306008,"domain_scores_codex":[0.9985539,0.0002719316,0.0002597094,0.0004599724,0.0000779903,0.0003765141],"domain_scores_gemma":[0.9992567,0.00007427625,0.0002073897,0.0003697725,0.00004285724,0.00004900612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002013309,0.0001022286,0.001568443,0.001011457,0.0004009609,0.00003228092,0.00006510255,0.000002267104,0.00001993813,0.00003093177,0.002200198,0.9943649],"study_design_scores_gemma":[0.0008286601,0.000134059,0.007032505,0.0006583728,0.0006807293,0.000598687,0.00001881076,0.000002125697,0.000002052575,0.00004156956,0.9897916,0.0002107766],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005975485,0.9954819,0.000006913146,0.001507838,0.0005022531,0.0006725295,0.0007276412,0.00001263204,0.0004907606],"genre_scores_gemma":[0.001971147,0.9945383,0.00005282302,0.0002056713,0.002109757,0.0008310046,0.0001912863,0.00003656733,0.00006345746],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9941541,"threshold_uncertainty_score":0.8258724,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2557666746","doi":"10.1016/s1470-2045(16)30559-9","title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Research UK; Clovis Oncology; Ovarian Cancer Research Fund; Stand Up To Cancer; Healthway; U.S. Department of Defense; National Ovarian Cancer Coalition; Ovarian Cancer Research Fund Alliance; American Association for Cancer Research","keywords":"Open label; Oncology; Medicine; Internal medicine; Ovarian carcinoma; Platinum; Ovarian cancer; Clinical trial; Cancer; Chemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.1468834883678543,"gpt":0.4311228869311657,"spread":0.2842393985633114,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001150592,0.0002327434,0.0007727897,0.0001212686,0.0001047013,0.0000373238,0.0005796755,0.0002370173,0.001007897],"category_scores_gemma":[0.000339951,0.0001415992,0.00004659438,0.000195227,0.0003100952,0.0002390186,0.0001493241,0.0004222669,0.0001539364],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007400271,"about_ca_system_score_gemma":0.000418356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004780208,"about_ca_topic_score_gemma":0.0005523255,"domain_scores_codex":[0.9974452,0.0007046135,0.0005866885,0.0004881607,0.0002766014,0.0004987682],"domain_scores_gemma":[0.9979091,0.0007639191,0.0003131701,0.0007196538,0.0001359455,0.0001582655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6919988,0.01199728,0.007571159,0.00003489165,0.0006844923,0.001704713,0.006598941,0.00001541807,0.07713088,0.05217449,0.07463478,0.07545417],"study_design_scores_gemma":[0.7415406,0.005069163,0.004681878,0.0001850904,0.0001027017,0.0002110055,0.0003704537,0.0003263455,0.007549476,0.002479778,0.2371656,0.0003179617],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9389584,0.00004559791,0.0001609815,0.04551269,0.002803525,0.00170189,0.0001864131,0.00007823498,0.01055228],"genre_scores_gemma":[0.9863991,0.0002041723,0.001874424,0.006392455,0.003567487,0.000322642,0.0001022633,0.00003761849,0.001099802],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1625308,"threshold_uncertainty_score":0.9999053,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2726463501","doi":"10.1016/s1470-2045(17)30441-2","title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1192,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Notre-Dame; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Radiosurgery; Brain metastasis; Radiation therapy; Clinical endpoint; Randomized controlled trial; Surgery; Metastasis; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.08135849473403658,"gpt":0.4090925863100155,"spread":0.327734091575979,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002454602,0.0004443947,0.00257668,0.0001098334,0.0007315984,0.0001558264,0.0003795094,0.00008323853,0.0002197917],"category_scores_gemma":[0.003421563,0.0002386943,0.0004549634,0.00009619639,0.0005079959,0.0001648218,0.00004422004,0.0003301608,0.00001550122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002981359,"about_ca_system_score_gemma":0.0007406669,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000925216,"about_ca_topic_score_gemma":0.0001685517,"domain_scores_codex":[0.9959203,0.001792267,0.000654209,0.0005550059,0.0003360981,0.000742141],"domain_scores_gemma":[0.989879,0.007388972,0.0007526823,0.001345208,0.0002309128,0.0004032948],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9533536,0.00279425,0.0001945695,0.00008766845,0.003830436,0.000869478,0.0009652078,0.00003592247,0.001311628,0.0002378555,0.03057709,0.005742304],"study_design_scores_gemma":[0.9027603,0.008063393,0.0006788808,0.00009724612,0.001914888,0.0001439699,0.0002653023,0.004800018,0.00009853654,0.00009568072,0.08081877,0.0002629651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7688495,0.001825972,0.002169946,0.2066916,0.000674672,0.01877068,0.0005701785,0.0001031831,0.0003442869],"genre_scores_gemma":[0.97341,0.0001195241,0.004913644,0.01282351,0.001444368,0.003772861,0.0004105512,0.0000999676,0.003005612],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2045605,"threshold_uncertainty_score":0.973367,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2095826876","doi":"10.1016/s1470-2045(09)70334-1","title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1187,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Adverse effect; Clinical endpoint; Internal medicine; Melanoma; Clinical trial; Intention-to-treat analysis; Phases of clinical research; Randomized controlled trial; Gastroenterology; Surgery; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03300815461349548,"gpt":0.3521155906350885,"spread":0.319107436021593,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056647,0.0002538181,0.0008265198,0.0001424006,0.00009655743,0.0000169206,0.0002054138,0.0001052391,0.00009288111],"category_scores_gemma":[0.00001877505,0.0001480776,0.00008670743,0.0004532576,0.00008662756,0.00008944559,0.00001433771,0.0003059412,0.000008896756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003258603,"about_ca_system_score_gemma":0.0001274515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009706428,"about_ca_topic_score_gemma":0.0002377467,"domain_scores_codex":[0.9982696,0.000236804,0.0004245672,0.0003465868,0.0002376412,0.0004848287],"domain_scores_gemma":[0.998999,0.0001501647,0.0001993442,0.0004992302,0.00008243728,0.00006984211],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8571087,0.005183978,0.03736975,0.00001116338,0.0003133106,0.00006805392,0.0032286,0.00003542776,0.0008870782,0.000005891516,0.00009378365,0.09569432],"study_design_scores_gemma":[0.8226077,0.01096222,0.1632927,0.00006380224,0.0001471496,0.000009921631,0.0005293525,0.00009203379,0.0003087837,0.00001086462,0.001798552,0.0001769449],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990895,0.0005197068,0.00002110932,0.001699416,0.000135964,0.004800705,0.000006296145,0.00008791396,0.001833865],"genre_scores_gemma":[0.9975108,0.0001477412,0.0002554978,0.001540789,0.0001452675,0.0001880558,0.00003379962,0.00002572873,0.0001523488],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1259229,"threshold_uncertainty_score":0.6038431,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2339311613","doi":"10.1016/s1470-2045(16)30033-x","title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1175,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"European Society for Medical Oncology; Boehringer Ingelheim","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Oncology; Population; Clinical endpoint; Randomized controlled trial; Epidermal growth factor receptor; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04042620639566981,"gpt":0.4065506950648967,"spread":0.3661244886692269,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002352811,0.0003075065,0.00142477,0.00007388002,0.0001933913,0.00002012219,0.0002023628,0.0001179528,0.000493466],"category_scores_gemma":[0.0001226553,0.0001415464,0.0001159827,0.0001615019,0.0001584755,0.00008705397,0.0000411895,0.00008712494,0.00001582127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009452555,"about_ca_system_score_gemma":0.001120376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000580292,"about_ca_topic_score_gemma":0.0004465189,"domain_scores_codex":[0.9982007,0.0002314077,0.0005529703,0.0003777637,0.000232213,0.0004049102],"domain_scores_gemma":[0.9968024,0.001705522,0.0005971078,0.000405926,0.0003468392,0.0001421456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9712113,0.007917766,0.001283275,0.00004638662,0.003003733,0.00007304434,0.002394652,0.00002792342,0.0002379191,0.0001118487,0.0008476084,0.01284453],"study_design_scores_gemma":[0.9616703,0.02868703,0.0007298147,0.0001602804,0.004510461,0.000004461681,0.000117229,0.0002494579,0.001016346,0.00001948099,0.002663488,0.0001716445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9650932,0.0005435644,0.0002460594,0.00524533,0.0006972963,0.01468585,0.0004183065,0.00003504416,0.01303537],"genre_scores_gemma":[0.9889732,0.0005944843,0.0005554717,0.0004622824,0.0006250659,0.006309278,0.0002389847,0.00004320517,0.002198035],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02388001,"threshold_uncertainty_score":0.5772094,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2136344041","doi":"10.1016/s1470-2045(14)70063-4","title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1174,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Montreal General Hospital","funders":"Universität Duisburg-Essen; Aarhus Universitet; Universität zu Köln; Universitair Medisch Centrum Groningen; University College London; National Institute for Health and Care Research; Universitaire Ziekenhuizen Leuven, KU Leuven; Canadian Cancer Society Research Institute; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; EORTC Charitable Trust; Aarhus Universitetshospital; Cancer Research UK; Amgen","keywords":"Ifosfamide; Doxorubicin; Soft tissue sarcoma; Medicine; Sarcoma; Oncology; Soft tissue; Chemotherapy; Internal medicine; Surgery; Pathology; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.1118737263595385,"gpt":0.4083463554134927,"spread":0.2964726290539542,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00108963,0.0004573594,0.004058494,0.0001411002,0.0001546137,0.00001312972,0.0002102709,0.0001453897,0.0001616165],"category_scores_gemma":[0.002464617,0.0002326739,0.0005131008,0.0001994622,0.0002413472,0.00004172239,0.00003880973,0.0001395516,0.00002627148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005502359,"about_ca_system_score_gemma":0.0003295789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001545679,"about_ca_topic_score_gemma":0.0008299924,"domain_scores_codex":[0.9969811,0.0005526704,0.001062565,0.0004846898,0.0002668901,0.0006520337],"domain_scores_gemma":[0.9864056,0.01175724,0.0005996271,0.0008047862,0.0002469491,0.0001857986],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8934473,0.005730473,0.00001535775,0.00008597766,0.001884602,0.0001462292,0.0006042848,0.0001430749,0.003375183,0.0003796969,0.001250534,0.09293731],"study_design_scores_gemma":[0.8750051,0.05835024,0.00005509326,0.00006787469,0.003784677,0.00006423535,0.0002344653,0.002716697,0.01203451,0.0002952006,0.04719972,0.0001921753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9553599,0.00295365,0.002601522,0.01909479,0.001457165,0.0174503,0.0001151242,0.0001278018,0.0008398037],"genre_scores_gemma":[0.987128,0.001037667,0.003831807,0.0009855713,0.001057013,0.005294026,0.0001492203,0.0000558137,0.0004609227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09274514,"threshold_uncertainty_score":0.9488167,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165413853","doi":"10.1016/s1470-2045(12)70425-4","title":"Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies","year":2012,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":1159,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of Child Health and Human Development; National Cancer Institute; Norwegian Institute of Public Health; University of California, San Francisco; University of North Carolina at Chapel Hill; Instituto Nacional De Salud Pública; Institut Gustave-Roussy; Wuhan University; Syddansk Universitet; Universidad de Costa Rica; Universitetet i Bergen; Odense Universitetshospital; Memorial Sloan-Kettering Cancer Center; Università degli Studi di Padova; Universiteit Maastricht; Imperial College London; World Health Organization; University of Southern California; University College London; Cancer Research UK; London School of Hygiene and Tropical Medicine; Loma Linda University; University of Otago; Shanghai Institute Of Planned Parenthood Research; Deutsches Krebsforschungszentrum; University of Pittsburgh; National and Kapodistrian University of Athens; Karolinska Institutet; Universidad de Chile; Institut National de la Santé et de la Recherche Médicale; University of Minnesota; Università degli Studi di Milano; University of Pennsylvania; Vanderbilt University; University of Toronto; National University of Singapore; Kaiser Permanente","keywords":"Menarche; Breast cancer; Epidemiology; Menopause; Medicine; Obstetrics; Gynecology; Cancer; Demography; Internal medicine; Sociology","retraction":null,"screen_n_in":null,"score":{"opus":0.5872332569421976,"gpt":0.511669772123417,"spread":0.07556348481878061,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004165146,0.000957547,0.0139725,0.0002246481,0.0003457753,0.00003480502,0.0005324906,0.0005386745,0.001759884],"category_scores_gemma":[0.0001278633,0.0004060066,0.0007297953,0.0007573954,0.0009481416,0.00009355676,0.0006723873,0.001749106,0.00001583535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001221995,"about_ca_system_score_gemma":0.0007993776,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008477413,"about_ca_topic_score_gemma":0.007884198,"domain_scores_codex":[0.9934278,0.002410116,0.0012186,0.001001579,0.0004886108,0.001453273],"domain_scores_gemma":[0.9939081,0.002890022,0.001617267,0.0009295276,0.0001774404,0.0004776628],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001095741,0.0002323164,0.02380867,0.001971158,0.6010848,0.00006736276,0.00449692,0.00002300333,9.687665e-7,0.00005863612,0.002661715,0.3644987],"study_design_scores_gemma":[0.0008772411,0.0002694694,0.03885682,0.0003568676,0.5218909,0.0001728482,0.000501747,0.000003033825,1.360019e-7,0.00008182286,0.4365939,0.0003951639],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.008762612,0.975996,0.000006762068,0.005318762,0.0002434208,0.001146455,0.00837463,0.00007288763,0.00007848358],"genre_scores_gemma":[0.02808107,0.9642375,0.0001561182,0.001386589,0.002517836,0.003280662,0.0001359491,0.00007341895,0.0001308492],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4339322,"threshold_uncertainty_score":0.9998392,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2963476376","doi":"10.1016/s1470-2045(19)30388-2","title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1153,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Merck Sharp and Dohme; Les Laboratories Pierre Fabre; Merck; Meso Scale Diagnostics; Roche; British Microcirculation Society; Amgen","keywords":"Ipilimumab; Pembrolizumab; Post-hoc analysis; Open label; Medicine; Post hoc; Oncology; Internal medicine; Clinical trial; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04835099458072202,"gpt":0.3901170919169451,"spread":0.3417660973362231,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001773703,0.0003504626,0.001847761,0.0001210652,0.0001126127,0.00005782685,0.0008537883,0.0002148316,0.0005762539],"category_scores_gemma":[0.0004221112,0.0002324201,0.000103411,0.0002704195,0.0001386342,0.0002308295,0.0001917475,0.0005255613,0.0001970639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004988312,"about_ca_system_score_gemma":0.0004467728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001786728,"about_ca_topic_score_gemma":0.003382797,"domain_scores_codex":[0.9963122,0.001094761,0.000905788,0.0007127291,0.0003246336,0.0006498776],"domain_scores_gemma":[0.9961311,0.001864285,0.0004195123,0.001296699,0.000146143,0.000142313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9470787,0.005226781,0.0006090507,0.00001207628,0.0006599836,0.0001683594,0.003352647,0.00001306828,0.01499745,0.00002317721,0.0006683393,0.02719035],"study_design_scores_gemma":[0.939757,0.03466911,0.005498376,0.00006015131,0.0003012871,0.0000153112,0.004935682,0.0005993159,0.0002429391,0.00002291363,0.01362242,0.0002755338],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764865,0.000868357,0.000001703189,0.004018663,0.001403491,0.008194679,0.000197304,0.00008014354,0.008749179],"genre_scores_gemma":[0.9952499,0.000465369,0.0003580199,0.002116715,0.000484726,0.0003376054,0.0002294415,0.00004963147,0.0007086106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02944233,"threshold_uncertainty_score":0.9477819,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2749747068","doi":"10.1016/s1470-2045(17)30517-x","title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Foothills Medical Centre; University of Calgary; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Celldex Therapeutics","keywords":"Temozolomide; Medicine; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Clinical trial; Chemotherapy; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.05302134748243224,"gpt":0.3716507209685209,"spread":0.3186293734860886,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004495143,0.0002859948,0.0008999619,0.00009677834,0.0004847942,0.000144012,0.0004816237,0.0001285091,0.00008499122],"category_scores_gemma":[0.0002416461,0.0001479315,0.0001477472,0.00005567251,0.0002829683,0.000187443,0.0001009164,0.000226044,0.00002021845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000205292,"about_ca_system_score_gemma":0.0002314671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009248185,"about_ca_topic_score_gemma":0.0003345678,"domain_scores_codex":[0.9983472,0.00009098108,0.0003517699,0.0004120582,0.0003310514,0.0004669944],"domain_scores_gemma":[0.9974843,0.0007115377,0.0005894551,0.0008169659,0.0002427644,0.0001550021],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9503551,0.003669396,0.02317857,0.00002352852,0.0008125104,0.0002635996,0.0002483571,0.00002519375,0.00009000496,0.00013727,0.002235575,0.01896086],"study_design_scores_gemma":[0.9425191,0.01237328,0.006859765,0.0001529643,0.0006015801,0.00005475304,0.0000441225,0.0001205548,0.0009141603,0.0000378086,0.03613635,0.0001855896],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822843,0.00005311795,0.0001213705,0.007335324,0.000661911,0.004903834,0.00006442433,0.00005351805,0.004522196],"genre_scores_gemma":[0.9938987,0.00004014841,0.001350909,0.0005907259,0.001680368,0.002169387,0.0001013359,0.00004481114,0.0001235866],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03390078,"threshold_uncertainty_score":0.6032472,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2117964602","doi":"10.1016/s1470-2045(11)70214-5","title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; Vancouver General Hospital; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; Université de Montréal; BC Cancer Agency; Princess Margaret Cancer Centre; Jewish General Hospital","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Internal medicine; Tolerability; Breast cancer; Ovarian cancer; Oncology; BRCA mutation; PARP inhibitor; Clinical endpoint; Triple-negative breast cancer; Adverse effect; Response Evaluation Criteria in Solid Tumors; Cancer; Serous fluid; Phases of clinical research; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.1110609224459381,"gpt":0.3838345029660907,"spread":0.2727735805201525,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005489644,0.0004359827,0.001580716,0.0001667605,0.0001725603,0.0000358586,0.0006359565,0.0001607938,0.001414203],"category_scores_gemma":[0.00008484234,0.0002312769,0.00004221551,0.0006834159,0.0002242908,0.0001734388,0.0001573509,0.0006481685,0.0000227457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008835015,"about_ca_system_score_gemma":0.0007893453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006409036,"about_ca_topic_score_gemma":0.01118922,"domain_scores_codex":[0.9965909,0.0009409626,0.0007150738,0.0006441341,0.00037275,0.0007362462],"domain_scores_gemma":[0.9978771,0.0003595689,0.0005279848,0.0007264408,0.0002818153,0.0002271161],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7266828,0.03020309,0.2116423,0.00007036807,0.0008462986,0.0003749674,0.01554461,0.000001817923,0.0002243253,0.00002249072,0.001875361,0.01251157],"study_design_scores_gemma":[0.473753,0.0114576,0.5127542,0.0001715633,0.0003452598,0.00003103232,0.0006887412,0.0001456352,0.0002365384,0.00002603242,0.0001521067,0.0002383171],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882612,0.00004453457,0.00003544999,0.001467127,0.000726463,0.008553026,0.000432243,0.00007256788,0.0004073596],"genre_scores_gemma":[0.9952415,0.00008360401,0.0006702085,0.001332646,0.000299715,0.001924507,0.00008638415,0.00006379875,0.0002976539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3011119,"threshold_uncertainty_score":0.9994987,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2145376545","doi":"10.1016/s1470-2045(15)70057-4","title":"Response assessment criteria for brain metastases: proposal from the RANO group","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1088,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University; Queen's University; London Health Sciences Centre; Ontario Institute for Cancer Research","funders":"Breast Cancer Research Foundation","keywords":"Group (periodic table); Computer science; Medicine; Medical physics; Psychology; Physics","retraction":null,"screen_n_in":null,"score":{"opus":0.2039613437360562,"gpt":0.5016602951475275,"spread":0.2976989514114713,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01617769,0.0005481637,0.003765142,0.00006371774,0.0002022048,0.00005689448,0.0006395446,0.0003295142,0.0003408011],"category_scores_gemma":[0.000807393,0.0002286617,0.0007372277,0.000201901,0.0002873988,0.0000350587,0.0002168463,0.0006728357,0.00009393352],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007189925,"about_ca_system_score_gemma":0.002605642,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001072172,"about_ca_topic_score_gemma":0.00008575148,"domain_scores_codex":[0.9873127,0.01043229,0.0007311326,0.0005794284,0.0003493666,0.00059507],"domain_scores_gemma":[0.9891884,0.008549438,0.0005227997,0.001451189,0.0001243403,0.000163822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003496071,0.0004387046,0.0000025611,0.001616627,0.002216417,0.0002166094,0.0001908455,1.158935e-7,0.000005420227,0.004270516,0.3247207,0.6628254],"study_design_scores_gemma":[0.005338097,0.002797542,0.00003930607,0.001311787,0.006925224,0.000319067,0.0001285986,0.000008735859,4.698593e-7,0.001279991,0.981631,0.0002201527],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000031946,0.9362866,0.0009778764,0.05165956,0.0009820051,0.006213633,0.003201957,0.00007766006,0.0005688191],"genre_scores_gemma":[0.00001754852,0.941184,0.03920492,0.008546957,0.00348979,0.003534156,0.002944974,0.0001291228,0.000948509],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6626053,"threshold_uncertainty_score":0.9324555,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"methods","study_design":"theoretical_or_conceptual","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2536769127","doi":"10.1016/s1470-2045(16)30532-0","title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1086,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Oncology; Maintenance therapy; Clinical endpoint; Internal medicine; Systemic therapy; Radiation therapy; Lung cancer; Performance status; Progression-free survival; Targeted therapy; Chemotherapy; Cancer; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.0456415097933536,"gpt":0.3758414789814968,"spread":0.3301999691881432,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005814531,0.0004309623,0.001490447,0.00006595936,0.0001639399,0.00002564146,0.0001967991,0.0001049938,0.0001171692],"category_scores_gemma":[0.0000773408,0.0001559099,0.000152035,0.0001682397,0.000188183,0.00009662446,0.00002561775,0.0001420664,0.000005959143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008429642,"about_ca_system_score_gemma":0.0004556876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007383709,"about_ca_topic_score_gemma":0.0004841051,"domain_scores_codex":[0.9976279,0.0004011612,0.0005455039,0.0005354154,0.0003125098,0.0005775391],"domain_scores_gemma":[0.9962934,0.001948763,0.0005708535,0.0005193506,0.0005413414,0.0001262797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.69973,0.006678372,0.2235446,0.0001287015,0.001874375,0.0000359629,0.002626143,0.00002155976,0.00006385303,0.000002916753,0.000359564,0.06493391],"study_design_scores_gemma":[0.9396849,0.02759197,0.02660388,0.001040283,0.0007770882,0.000005309029,0.0005176284,0.000876515,0.0006588357,0.00000507106,0.001973076,0.0002654273],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9668931,0.002831329,0.002080287,0.00290121,0.00043788,0.02463568,0.0001204925,0.00005715245,0.00004291334],"genre_scores_gemma":[0.9609918,0.01015834,0.0004724688,0.00112328,0.0003138554,0.02660887,0.00003165775,0.00006521489,0.0002345391],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2399549,"threshold_uncertainty_score":0.635782,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2164437838","doi":"10.1016/s1470-2045(15)00222-3","title":"Expanding global access to radiotherapy","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1085,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University; Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"World Health Organization","keywords":"Radiation therapy; Low and middle income countries; Middle income; Developed country; Developing country; Medicine; Business; Economic growth; Economics; Environmental health; Demographic economics; Surgery; Population","retraction":null,"screen_n_in":null,"score":{"opus":0.20159668286846,"gpt":0.5736985221372256,"spread":0.3721018392687656,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001297493,0.0004636824,0.004259186,0.0001065707,0.0001385285,0.00003002571,0.001170046,0.0007623435,0.0002995657],"category_scores_gemma":[0.0001610394,0.0002540422,0.0003508593,0.0006342197,0.000313041,0.00007369484,0.00018372,0.0008456046,0.0002082018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002893731,"about_ca_system_score_gemma":0.001677346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008389487,"about_ca_topic_score_gemma":0.00002015232,"domain_scores_codex":[0.9973544,0.0006679068,0.0005592403,0.0005113191,0.0002388977,0.0006682451],"domain_scores_gemma":[0.9977623,0.0005567817,0.0003656335,0.0009576955,0.00008443539,0.0002731821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003457802,0.00008404566,0.00005271237,0.00120462,0.0004126118,0.0001578522,0.0001166035,0.000003207499,2.877857e-7,0.0004683402,0.1317257,0.8654282],"study_design_scores_gemma":[0.001709877,0.001005469,0.00001811753,0.001528246,0.0006066835,0.002096134,0.00001778446,0.000001787312,1.709492e-7,0.0004440537,0.9923059,0.0002658122],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000005622548,0.9643009,0.001579995,0.005964874,0.002972916,0.001849262,0.00005554176,0.0001509422,0.02311995],"genre_scores_gemma":[8.413055e-7,0.9708995,0.005134226,0.01268218,0.009578824,0.0003545623,0.00004650602,0.00006256875,0.001240857],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8651624,"threshold_uncertainty_score":0.9999912,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2142875113","doi":"10.1016/s1470-2045(07)70278-4","title":"Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1078,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Saint John Regional Hospital; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Axillary Lymph Node Dissection; Sentinel lymph node; Breast cancer; Surgery; Lymph node; Stage (stratigraphy); Randomized controlled trial; Dissection (medical); Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02027302097998062,"gpt":0.3380045078926205,"spread":0.3177314869126399,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001142725,0.000222284,0.0006181591,0.00003735048,0.0001593836,0.00001127865,0.000208375,0.0002223186,0.00001313545],"category_scores_gemma":[0.0003240648,0.0001263752,0.0001120401,0.0001470199,0.0005049808,0.000009351066,0.0001383173,0.0001868182,9.000216e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001419495,"about_ca_system_score_gemma":0.0001491247,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001191094,"about_ca_topic_score_gemma":0.0009507845,"domain_scores_codex":[0.9979548,0.0003776613,0.0006895441,0.0004424267,0.0002241823,0.0003113181],"domain_scores_gemma":[0.9980742,0.0008222028,0.0005014159,0.0003780635,0.0001747347,0.00004934397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5503063,0.0007268611,0.4446199,0.000006158222,0.0003695264,0.000003404815,0.0001403604,0.00003061617,0.0009291175,0.00001943654,0.0002058535,0.002642489],"study_design_scores_gemma":[0.3164681,0.0003096356,0.6822639,0.00002886499,0.0001220179,0.000007616974,0.0001030364,0.00001368623,0.0003967869,0.00006887085,0.0001116953,0.0001059086],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941274,0.0001241258,0.0003312444,0.003447084,0.0003352087,0.0007257243,0.0005162928,0.00001618326,0.0003767685],"genre_scores_gemma":[0.9979325,0.0002984931,0.0002177712,0.0005166775,0.000604265,0.0001336768,0.000249499,0.00001825734,0.0000288546],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.237644,"threshold_uncertainty_score":0.5153432,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2973153606","doi":"10.1016/s1470-2045(19)30456-5","title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1052,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; Nova Scotia Health Authority; Government of New Brunswick; Canadian Partnership Against Cancer; Dr. H. Bliss Murphy Cancer Centre; Saskatchewan Cancer Agency; CancerCare Manitoba; Cancer Care Ontario; Alberta Health Services","funders":"Department of Health, Government of Western Australia; Public Health Agency; Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Cancer Society of New Zealand; Cancer Institute NSW; Kreftforeningen; Cancer Research UK; World Health Organization; Cancer Focus Northern Ireland; Northern Ireland Environment Agency; Kræftens Bekæmpelse; Scottish Government","keywords":"Medicine; Cancer; Population; Colorectal cancer; Incidence (geometry); Demography; Cancer registry; Lung cancer; Stomach cancer; Environmental health; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1223546848596375,"gpt":0.4346419930388014,"spread":0.3122873081791639,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002293582,0.0001802976,0.0008471482,0.0001204182,0.00005297649,0.0000257738,0.0002497996,0.0001268278,0.0001367368],"category_scores_gemma":[0.00008993111,0.0001309862,0.00002972584,0.0003465458,0.000108222,0.0001194065,0.0001167649,0.0004090008,0.00001918584],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005362838,"about_ca_system_score_gemma":0.0004219146,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0489264,"about_ca_topic_score_gemma":0.1963481,"domain_scores_codex":[0.9978686,0.0004953598,0.0004235514,0.0003698765,0.0004067473,0.000435841],"domain_scores_gemma":[0.9987913,0.0004431938,0.0001732892,0.0004401971,0.00008485517,0.00006711501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008594636,0.0001133067,0.9969086,0.0001103868,0.00003306116,0.0001149945,0.0006681848,0.0003004032,0.000006873604,0.0002369062,0.00009604252,0.0005518001],"study_design_scores_gemma":[0.004206318,0.0006788995,0.9928861,0.0002387477,0.00004714908,0.000009321746,0.000508541,0.0005646463,0.000005894007,0.000217403,0.0004905137,0.0001464675],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917973,0.001083825,0.00000256904,0.005267325,0.0003533576,0.00121541,0.00001974121,0.00003654444,0.0002238979],"genre_scores_gemma":[0.9980345,0.0001159312,0.00008826125,0.001258727,0.0002293045,0.0001939968,0.00001483376,0.00001546863,0.00004896572],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1474217,"threshold_uncertainty_score":0.9574069,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2113322173","doi":"10.1016/s1470-2045(12)70559-4","title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1029,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Health Sciences Centre; Western University; Sunnybrook Health Science Centre; University of Calgary","funders":"National Cancer Institute","keywords":"Renal cell carcinoma; Medicine; Prognostic model; Population; Oncology; Database; Internal medicine; Computer science; Overall survival; Environmental health","retraction":null,"screen_n_in":null,"score":{"opus":0.08719604319912287,"gpt":0.3307886472917002,"spread":0.2435926040925773,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003376639,0.0001409436,0.0004121358,0.00005288918,0.00005916375,0.00001766554,0.0001839828,0.00002811972,0.00006354127],"category_scores_gemma":[0.00003396246,0.00006930059,0.00003808537,0.00008382984,0.00009107333,0.00007715075,0.00006587522,0.0001584253,0.000005051768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001182073,"about_ca_system_score_gemma":0.0001570208,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000826339,"about_ca_topic_score_gemma":0.0001843413,"domain_scores_codex":[0.9987009,0.0002622861,0.000314418,0.0002153082,0.0003420332,0.0001650761],"domain_scores_gemma":[0.9988335,0.000256993,0.0002808384,0.0004347843,0.0001417934,0.00005207891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006956387,0.0009995666,0.9602619,0.00006340569,0.0001168925,0.00000916437,0.0007516562,0.03161767,0.004856476,0.0002513619,0.0001367972,0.0002394819],"study_design_scores_gemma":[0.007798423,0.00152078,0.5654354,0.00007328937,0.0008159787,0.00004211209,0.0004360548,0.4177311,0.005337233,0.0006617105,0.00002350987,0.0001243783],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913383,0.00009765066,0.004361558,0.001557979,0.00005502073,0.001719255,0.00002405057,0.00001637038,0.0008297745],"genre_scores_gemma":[0.9946337,0.000001545256,0.004535074,0.0003490778,0.00005652527,0.0002261655,0.00003222515,0.0000183102,0.0001473736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3948264,"threshold_uncertainty_score":0.2825996,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2161689638","doi":"10.1016/s1470-2045(11)70175-9","title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1028,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Hepatocellular carcinoma; Liver transplantation; Transplantation; Consensus conference; Listing (finance); Donation; Family medicine; Internal medicine; Political science; Law","retraction":null,"screen_n_in":null,"score":{"opus":0.3238269917420179,"gpt":0.3579941574896356,"spread":0.03416716574761769,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005455621,0.000114208,0.0002894036,0.00005038437,0.0001185525,0.000009899211,0.0001351713,0.0001079975,0.0002426555],"category_scores_gemma":[0.00006060768,0.00008404804,0.0001037779,0.00004336895,0.00008508317,0.00005253317,0.00001061874,0.00009154808,0.00001043165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007649895,"about_ca_system_score_gemma":0.0001735966,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001428544,"about_ca_topic_score_gemma":0.00008122963,"domain_scores_codex":[0.9991122,0.00009164185,0.0002679465,0.0002355781,0.00007522889,0.0002173324],"domain_scores_gemma":[0.9990556,0.0002175436,0.0001361125,0.0002704435,0.0002474639,0.00007285395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006885692,0.00100538,0.9117855,0.0002928759,0.0004841633,0.001857377,0.009229869,2.693343e-7,0.002652665,0.02642221,0.01226849,0.0271155],"study_design_scores_gemma":[0.02456467,0.007811646,0.1775196,0.000100961,0.002993569,0.007750353,0.001314498,0.05331543,0.03644729,0.008928683,0.6785483,0.0007049508],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.963594,0.000086031,0.01034032,0.01400519,0.0006029145,0.001916698,0.0002259014,0.00007598497,0.009152965],"genre_scores_gemma":[0.9668106,0.0001637412,0.02955289,0.0006041966,0.0004481109,0.0006464468,0.001228759,0.00001727841,0.0005279888],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7342659,"threshold_uncertainty_score":0.342738,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2101922439","doi":"10.1016/s1470-2045(14)70379-1","title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":1019,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck KGaA","keywords":"Temozolomide; Medicine; Chemoradiotherapy; Internal medicine; Oncology; Clinical endpoint; Phases of clinical research; Progression-free survival; Clinical trial; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.04591526199650049,"gpt":0.3746563513188675,"spread":0.3287410893223671,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001218708,0.0005015694,0.001875869,0.0001904439,0.000272637,0.0001067189,0.0005192494,0.0001400646,0.0001586025],"category_scores_gemma":[0.0005677318,0.0002380459,0.0000734693,0.0005380507,0.0002552918,0.0001131292,0.0001484048,0.0003664224,0.00002236399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007629987,"about_ca_system_score_gemma":0.0007034863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001292195,"about_ca_topic_score_gemma":0.0009742738,"domain_scores_codex":[0.9957612,0.001188058,0.0005673053,0.000754226,0.0007757216,0.0009534852],"domain_scores_gemma":[0.9956366,0.001912193,0.0003959926,0.0009753327,0.000702846,0.0003770769],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.946687,0.02015352,0.003415984,0.0000648938,0.001184298,0.0003704778,0.00108333,0.00002531266,0.0002019955,0.00001771386,0.001008347,0.02578706],"study_design_scores_gemma":[0.6979056,0.2866893,0.0007558184,0.00008183545,0.0008794467,0.00001657043,0.0002148232,0.0009085794,0.0008150163,0.00001243349,0.01148046,0.0002401905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9659881,0.0000365953,0.000990556,0.001379517,0.0001057528,0.03064293,0.00008805726,0.0001046319,0.0006638613],"genre_scores_gemma":[0.9897329,0.00004495761,0.004629586,0.0004585425,0.0002976069,0.003887892,0.000180294,0.0001234306,0.0006448383],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2665357,"threshold_uncertainty_score":0.970723,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2804105316","doi":"10.1016/s1470-2045(18)30292-4","title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1011,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"Astex Pharmaceuticals; Novartis","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Hormone receptor; Endocrine system; Hormone therapy; Gynecology; Cancer; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.03244725651231038,"gpt":0.3715379082167767,"spread":0.3390906517044663,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006434701,0.0004429968,0.001435083,0.00008500854,0.0002995978,0.00002369784,0.0003842022,0.0001242978,0.0007307226],"category_scores_gemma":[0.00005829521,0.0002654959,0.0001093983,0.0002980472,0.000845491,0.0001793721,0.00005855953,0.0003673904,0.0000251718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001101276,"about_ca_system_score_gemma":0.0008761207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005566329,"about_ca_topic_score_gemma":0.00006673896,"domain_scores_codex":[0.9971992,0.0002597807,0.0004852153,0.0005944814,0.000351376,0.001109918],"domain_scores_gemma":[0.9977175,0.0005559595,0.000395161,0.0006271054,0.0004687953,0.0002354821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7863739,0.0005952446,0.00003480255,0.00002703694,0.000775877,0.00001708837,0.001609225,0.00001822545,0.06990329,0.0001286896,0.001461492,0.1390552],"study_design_scores_gemma":[0.751824,0.02633149,0.001157779,0.0000683643,0.0001533673,0.0002564259,0.0003196104,0.00009108242,0.00536067,0.0002548399,0.2138532,0.0003291532],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9734614,0.001519633,0.001947276,0.01364763,0.0006891019,0.006877567,0.0005947945,0.0002318749,0.001030644],"genre_scores_gemma":[0.9709054,0.0009339511,0.004088308,0.005397411,0.008384014,0.008894483,0.00008738841,0.0001381065,0.001170922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2123917,"threshold_uncertainty_score":0.9999797,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2111404068","doi":"10.1016/s1470-2045(14)70012-9","title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":978,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Medical Research Council; National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Genentech; F. Hoffmann-La Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Population; Oncology; Progression-free survival; Metastatic melanoma; Chemotherapy; Cancer research; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0286159142605539,"gpt":0.3339014764236995,"spread":0.3052855621631456,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001177818,0.0001563678,0.0006707869,0.00004802115,0.00006217627,0.00001137866,0.0003044803,0.0001244429,0.000008163393],"category_scores_gemma":[0.0002849355,0.0001159535,0.00003185165,0.00008858667,0.0002112981,0.000007345978,0.00027289,0.0001105545,9.119393e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001212918,"about_ca_system_score_gemma":0.00008710973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001272675,"about_ca_topic_score_gemma":0.0004234443,"domain_scores_codex":[0.9982852,0.000672221,0.0004170081,0.0003223228,0.00008594214,0.0002173029],"domain_scores_gemma":[0.9989133,0.0003558692,0.0002529949,0.0003504614,0.00006953995,0.00005783344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1172393,0.005918985,0.007428633,0.0001367205,0.0006628266,0.00005551344,0.006525965,0.00001631739,0.7131909,0.003644714,0.0005567797,0.1446234],"study_design_scores_gemma":[0.7619356,0.02393308,0.09174892,0.00008302523,0.0003469131,0.0001807637,0.001429412,0.0005928241,0.1112797,0.0009786859,0.006951217,0.0005398071],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950681,0.0003128666,0.0003243542,0.0002511799,0.0001079808,0.001132981,0.00004151374,0.000004699333,0.002756287],"genre_scores_gemma":[0.9989465,0.0001276906,0.0003713453,0.0001959751,0.0001076383,0.00004793514,0.00005143386,0.00001399194,0.0001375275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6446963,"threshold_uncertainty_score":0.4728448,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2560704457","doi":"10.1016/s1470-2045(16)30624-6","title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":961,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Toronto; McMaster University","funders":"National Cancer Institute; University of Oxford","keywords":"Nivolumab; Ipilimumab; Medicine; Tolerability; Internal medicine; Lung cancer; Oncology; Cancer; Surgery; Adverse effect; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.08906368332496893,"gpt":0.4350249849294019,"spread":0.345961301604433,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008862526,0.0003071885,0.001140916,0.00006967179,0.0001797563,0.00001596689,0.0005466697,0.0001439016,0.0001251197],"category_scores_gemma":[0.00007398571,0.000165169,0.00008680905,0.0001661566,0.0001742343,0.0001143465,0.0001184997,0.0001081853,0.000008291192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001125709,"about_ca_system_score_gemma":0.0007695555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002656492,"about_ca_topic_score_gemma":0.006618577,"domain_scores_codex":[0.9978866,0.0001715628,0.0006808084,0.0005446956,0.0001737558,0.0005425901],"domain_scores_gemma":[0.9978306,0.0004372116,0.0004359931,0.0009868011,0.0001849954,0.0001244466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4225556,0.01620611,0.001232039,0.0002137974,0.001505393,0.00009089513,0.005119286,0.00005194705,0.1997503,0.00001297306,0.002281403,0.3509803],"study_design_scores_gemma":[0.743577,0.09012265,0.002595145,0.0003769568,0.001264825,0.0000464164,0.001078899,0.002334652,0.06256197,0.00004216236,0.09554219,0.0004571658],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846685,0.0009711917,0.0001392469,0.005578604,0.0005047849,0.006190637,0.0004330784,0.0000574489,0.001456516],"genre_scores_gemma":[0.9865239,0.002748437,0.001261392,0.0007417434,0.0005055752,0.001851879,0.00005593999,0.00005771888,0.006253385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3505231,"threshold_uncertainty_score":0.6735398,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121847974","doi":"10.1016/s1470-2045(15)70127-0","title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":955,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Bevacizumab; FOLFIRI; Ramucirumab; Medicine; Oxaliplatin; Oncology; Internal medicine; Colorectal cancer; Second-line therapy; Placebo; Chemotherapy; Overall survival; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.09086894514201639,"gpt":0.3537783983077336,"spread":0.2629094531657172,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000459883,0.0003986629,0.001198616,0.0001837478,0.0001114915,0.0000318239,0.0001111975,0.00006733317,0.00004965108],"category_scores_gemma":[0.00004839051,0.0001919576,0.00003070219,0.0004020326,0.0002194214,0.000146025,0.00006991912,0.0003031367,0.000001479491],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004734641,"about_ca_system_score_gemma":0.0002856858,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002046667,"about_ca_topic_score_gemma":0.03123084,"domain_scores_codex":[0.9979714,0.0002627322,0.0003807555,0.0004861631,0.0004067153,0.000492264],"domain_scores_gemma":[0.9987286,0.000394301,0.0002531028,0.0002860781,0.0002007328,0.000137186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6018692,0.004607948,0.3820623,0.00005682293,0.0004390175,0.0005178199,0.008939328,0.00002748949,0.000002343682,0.000001073553,0.000007112916,0.001469523],"study_design_scores_gemma":[0.6475266,0.05345634,0.2960895,0.00008615061,0.0003307181,0.00003776249,0.001871094,0.0002378239,0.0001261222,0.000003146347,0.00005013684,0.0001845656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888409,0.0005595019,0.000002791737,0.0008455443,0.00008087163,0.009438425,0.00002527852,0.0000415717,0.00016507],"genre_scores_gemma":[0.9965404,0.00006132277,0.0002687185,0.00007419139,0.00005921815,0.0028275,0.000059529,0.00004356354,0.00006552642],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08597283,"threshold_uncertainty_score":0.9864467,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152905269","doi":"10.1016/s1470-2045(12)70087-6","title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Gefitinib; Internal medicine; Clinical endpoint; Hazard ratio; Placebo; Lung cancer; Oncology; Performance status; Chemotherapy; Adenocarcinoma; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.03765453655497886,"gpt":0.403575366148624,"spread":0.3659208295936452,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003379942,0.0002391219,0.001087578,0.00006591623,0.00006344567,0.000006362424,0.00009950212,0.0000724796,0.0002678263],"category_scores_gemma":[0.0001129962,0.0001242375,0.00009426897,0.0001504936,0.0001549481,0.00009107152,0.00002267321,0.0001230417,5.733701e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001139655,"about_ca_system_score_gemma":0.000561789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005119908,"about_ca_topic_score_gemma":0.0002688627,"domain_scores_codex":[0.9986141,0.0001105615,0.0004716511,0.0002292963,0.0001736069,0.0004007506],"domain_scores_gemma":[0.9977745,0.001144522,0.0004864449,0.0002830955,0.0001958086,0.0001155962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.975596,0.002711663,0.004561319,0.0007667326,0.001480576,0.000004393827,0.004030999,0.00001836582,0.0006087182,0.00002093107,0.0006881423,0.009512194],"study_design_scores_gemma":[0.9785327,0.00999559,0.00135243,0.0002539148,0.003679655,0.000005219171,0.0005117324,0.0002212097,0.001839414,0.000008430234,0.003420289,0.0001793807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895627,0.0009952454,0.0004913916,0.0009808997,0.000369853,0.006951853,0.0003394553,0.00002048766,0.0002880761],"genre_scores_gemma":[0.9720966,0.0004026507,0.02235164,0.0004536573,0.0006859982,0.003341239,0.00008571102,0.0000552057,0.0005272701],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02186025,"threshold_uncertainty_score":0.506626,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2106285196","doi":"10.1016/s1470-2045(10)70223-0","title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":944,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"Ligue Contre le Cancer; AstraZeneca; American Society for Radiation Oncology","keywords":"Medicine; Goserelin; Androgen suppression; Prostate cancer; Clinical endpoint; Urology; Cyproterone acetate; Radiation therapy; Androgen; Prostate; Antiandrogen; Internal medicine; Androgen deprivation therapy; Randomized controlled trial; Medroxyprogesterone acetate; Cancer; Surgery; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.03438830034005187,"gpt":0.3603229668372296,"spread":0.3259346664971777,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007597491,0.000198433,0.00081946,0.00005134102,0.0001057902,0.00001667558,0.0001352857,0.00005193921,0.0001231819],"category_scores_gemma":[0.00007024668,0.00008693463,0.00004046428,0.0001088538,0.0001476016,0.00008919533,0.00002201003,0.0002046335,0.000001901024],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009279698,"about_ca_system_score_gemma":0.0003982228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005926525,"about_ca_topic_score_gemma":0.00696741,"domain_scores_codex":[0.9985611,0.0002249337,0.0003402234,0.0003443095,0.0002299811,0.0002994293],"domain_scores_gemma":[0.9983731,0.0003216902,0.0004982656,0.0004908101,0.0002013877,0.0001147264],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4010421,0.001879125,0.5715702,0.0001391041,0.0007841198,0.0001210374,0.003212213,0.0001015254,0.001692203,0.00001161543,0.0003111462,0.01913565],"study_design_scores_gemma":[0.2749784,0.02867135,0.6815017,0.0002086746,0.002158569,0.00008789326,0.0003593748,0.0002278036,0.01084825,0.00005320646,0.0007166109,0.0001881012],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934013,0.0001086632,0.00004600349,0.0007757769,0.0001411471,0.005058192,0.0003688506,0.00003201823,0.00006803534],"genre_scores_gemma":[0.9936917,0.0002690543,0.003112249,0.0001066659,0.0002814379,0.002073558,0.0001138481,0.00003488726,0.0003165761],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1260637,"threshold_uncertainty_score":0.3887978,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2415950182","doi":"10.1016/s1470-2045(16)30107-3","title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":939,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Exelixis; Memorial Sloan-Kettering Cancer Center","keywords":"Cabozantinib; Everolimus; Meteor (satellite); Renal cell carcinoma; Medicine; Open label; Oncology; Internal medicine; Clinical trial; Astronomy; Physics","retraction":null,"screen_n_in":null,"score":{"opus":0.1614115617390091,"gpt":0.3921593036737883,"spread":0.2307477419347792,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001363339,0.0003413868,0.001406378,0.0001147103,0.00009505507,0.00002392046,0.0006361691,0.0002292136,0.0002489811],"category_scores_gemma":[0.0007576591,0.000184545,0.000116512,0.0002385745,0.0002064853,0.0001231055,0.00025643,0.0003953345,0.0002037055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005675027,"about_ca_system_score_gemma":0.0006409242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007244276,"about_ca_topic_score_gemma":0.0004970331,"domain_scores_codex":[0.9965822,0.000859413,0.0008136334,0.0006961505,0.0003174539,0.0007311752],"domain_scores_gemma":[0.9951292,0.003142843,0.0003994285,0.001037599,0.00008756793,0.0002033905],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9172742,0.001617879,0.0001533336,0.000009779518,0.00009035854,0.001128314,0.0003778183,0.000002498057,0.0411198,0.00003507179,0.004755409,0.03343559],"study_design_scores_gemma":[0.9237135,0.01598913,0.002471886,0.00007186712,0.0002832348,0.00004249788,0.00006830324,0.00003029889,0.02002587,0.0001327893,0.03695257,0.0002180409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9624029,0.000490262,0.00002107638,0.006424485,0.001101467,0.002983615,0.0002819964,0.00004646546,0.02624769],"genre_scores_gemma":[0.993469,0.000190913,0.001700841,0.0005517947,0.0013884,0.0004392437,0.0001273703,0.00003959263,0.002092863],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03321755,"threshold_uncertainty_score":0.7525526,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}